- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01484470
Umbilical Cord Transplantation for the Elderly Population
August 19, 2019 updated by: Patrick Stiff, Loyola University
While cord blood transplants have been performed safely in elderly patients, many still relapse.
The investigators propose to intensify the preparative regimen for this patient group in an attempt to decrease relapses, and combine this with an ex vivo expanded Umbilical Cord Blood (UCB) unit.
Study Overview
Detailed Description
Allogeneic stem cell transplantation is a life saving procedure in selected high-risk or recurrent hematologic malignancies and marrow failure syndromes.
However its wide application is limited by availability of suitably HLA matched adult donors.
Umbilical Cord Blood (UCB) has been increasingly used as an alternative hematopoietic stem cell source for these patients.
To date, over 10,000 UCB transplants have been performed in both children32-38 and adults.35,39-44
Its advantages include easier procurement, decreased risk to donors, reduced risk of transmitting infections, the immediate availability of cryopreserved units, and acceptable HLA mismatches.
The transplantation of UCB allows a greater degree of HLA mismatching without an unacceptably high incidence of graft versus host disease (GVHD).
Adult patients receiving myeloablative cord blood transplants have a 90% chance of engraftment, but carry a 50% rate of transplant related mortality.
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Maywood, Illinois, United States, 60153
- Loyola University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
55 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ages 55-73
Patients will have one of the following malignancies:
- Acute myelogenous leukemia (AML) deNovo in first CR with adverse cytogenetic abnormalities, M0, M6, M7 subtypes, extramedullary disease in remission or high CD34+ disease (> 50%)
- AML in early relapse (5-10% blasts on bone marrow aspirate or biopsy), or beyond CR-1 with no circulating blasts
- AML at any time if resulting from a previous myelodysplasia
- Acute lymphocytic leukemia or lymphoblastic lymphoma (ALL) in first CR with adverse prognostic features: t (9; 22), extra medullary disease, or mature B cell phenotype
- Acute lymphoid leukemia or lymphoblastic lymphoma in early relapse (5- 10% blasts on aspirate), or beyond CR-1
- Acute Undifferentiated Leukemia or biphenotypic leukemia in CR1 or CR2
- Transfusion dependent myelodysplastic syndrome (MDS) or refractory anemia with excess blasts (RAEB) or RAEB-in transition, CMMOL, or any myelodysplasia with 7q-, 5q-, 7-, 5- or resulting from prior anti cancer therapy.
- Relapsed Non-Hodgkin's Lymphoma (NHL), including those that have relapsed after an autologous marrow/blood stem cell transplant
- Chronic lymphocytic leukemia (CLL) patient who has had fludarabine and either failed or relapsed. Prior autologous transplant patients are eligible.
- Patients with adequate organ function and performance status criteria
Subject must have at least one or the following back-up stem cell sources in case of engraftment failure:
- Subject is willing to undergo BM harvest or peripheral blood progenitor cells (PBPC) collection for use in case of engraftment failure (when clinically applicable).
- Subject has a second CBU as a possible back up.
- Subject's haploidentical family member has been identified and agreed (by signing a written informed consent) to donate hematopoietic stem cells in case of engraftment failure.
- Evaluation by social service/psychologist
- Subject signs the written informed consent after being aware of the nature of the subject's disease and willingly consents to the treatment program after being informed of alternative treatments, potential risks, benefits and discomforts.
- Ability to understand and agree to compliance with strict evaluation, isolation,and medication schedules
- Designated primary care giver.
- Dental evaluation/treatment completed.
- ENT evaluation/treatment completed.
- All patient who survive to day 90 are eligible for measurement of T and B cell function and lymphocyte subset numbers to determine immune reconstitution post UCB transplantation with or without StemEx®
Exclusion Criteria:
- Patient with suitable related donor as defined per institutional guidelines
- Chemotherapy resistant or active AML, ALL, AUL, biphenotypic leukemia
- AML evolved from myelofibrosis
- MDS with 20% or greater bone marrow blasts at pre-transplant workup. Patients may receive therapy and if in remission, are eligible
- Prior allogeneic hematopoeitic stem cell transplant at any time
- Less than twenty-one days have elapsed since the subject's last radiation or chemotherapy prior to conditioning (except for hydroxyurea)
- Uncontrolled bacterial, fungal or viral infection at the time of study enrollment
- Seropositive or NAT positive for HIV, HTLV-1 and Hepatitis C
- Subjects with signs and symptoms of active central nervous system (CNS) disease
- Females who are pregnant or breastfeeding
- Allergy to bovine proteins or to aminoglycoside antibiotics (e.g. gentamicin) or to any product, which may interfere with the treatment.
- Patient unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up and research tests.
- Enrolled in another clinical trial or received an investigational treatment during the last 30 days, unless approved by the primary investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Unmanipulated arm
Participants that do not meet criteria for StemEx®, will be registered into the unmanipulated UCB arm and receive the standard conditioning regimen.
|
|
Experimental: Stemx Arm
StemEx is a stem/progenitor cell-based product of ex-vivo expanded allogeneic UCB, which is administered to the subject in combination with the non-manipulated portion of the same cord blood unit (CBU).
The CBU must be cryopreserved in two portions of which the larger (or equal) CBU portion contains at least 1.5 x 107 total nucleated cells (TNC)/Kg.
This portion remains unmanipulated and is transplanted on Day 0. StemEx is derived from the smaller (or equal) CBU portion, which is expanded ex vivo for 21 days starting pre-transplant in the presence of cytokines TPO, IL-6, Flt-3L and SCF at a concentration of 50ng/ml and 5μM tetraethylenepentamine (TEPA)
|
For patients allocated to StemEx® arm:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of StemEx
Time Frame: 100 days
|
The primary endpoint is to demonstrate the efficacy of StemEx® vs. unmanipulated UCB transplantation in the elderly population (>55years of age) following RIC regimen by demonstrating engraftment with full donor chimerism (>98%) by Day 100 of more than 60% of the patients who received transplants expanded by the StemEx method.
|
100 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to engraftment
Time Frame: 42 days
|
The day of neutrophil engraftment is defined as the first day of 3 consecutive days of an ANC greater than 500/microliter.
The platelet recovery is the first of 3 consecutive measurements tested on different days of a platelet count greater than or equal to 20,000 without requiring platelet transfusions in the previous 7 days.
Patients will be monitored for donor cell engraftment as evidenced by neutrophil recovery and donor chimerism in the marrow and/or peripheral blood at serial time points post transplant.
|
42 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Patrick Stiff, MD, Loyola Universtiy Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
November 21, 2018
Study Completion (Actual)
November 21, 2018
Study Registration Dates
First Submitted
November 30, 2011
First Submitted That Met QC Criteria
December 1, 2011
First Posted (Estimate)
December 2, 2011
Study Record Updates
Last Update Posted (Actual)
August 21, 2019
Last Update Submitted That Met QC Criteria
August 19, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202041
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Malignancies
-
Cooperative Study Group A for HematologyCompletedHEMATOLOGIC MALIGNANCIESKorea, Republic of
-
Fondazione EMN Italy OnlusCompletedHEMATOLOGIC MALIGNANCIESItaly
-
Medical College of WisconsinCompletedMalignancies, HematologicUnited States
-
Sinocelltech Ltd.RecruitingRelapsed or Refractory Hematologic MalignanciesChina
-
Vanda PharmaceuticalsUnknownRelapsed or Refractory Hematologic MalignanciesUnited States
-
Washington University School of MedicineRecruitingPediatric Hematologic MalignanciesUnited States
-
Precision BioSciences, Inc.RecruitingHematologic Malignancy | CD19 Expressing MalignanciesUnited States
-
Constellation PharmaceuticalsNot yet recruitingSolid Tumor | Hematologic Malignancy | Advanced Malignancies
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingAdvanced Solid Tumors and Hematologic MalignanciesChina
-
Suzhou Junjing BioSciences Co., Ltd.RecruitingAdvanced Solid Tumors | Advanced Hematologic MalignanciesChina
Clinical Trials on StemEx
-
Gamida Cell -Teva Joint Venture Ltd.CompletedAcute Myeloid Leukemia | Myelodysplastic Syndromes | Non-Hodgkin's Lymphoma | Chronic Myeloid Leukemia | Hematologic Malignancies | Hodgkin's Disease | Lymphoid LeukemiaUnited States, Israel, Hungary, Italy, Spain